| First Author | Triscott J | Year | 2025 |
| Journal | Mol Cancer Res | Volume | 23 |
| Issue | 1 | Pages | 33-45 |
| PubMed ID | 39382632 | Mgi Jnum | J:361599 |
| Mgi Id | MGI:7860952 | Doi | 10.1158/1541-7786.MCR-24-0290 |
| Citation | Triscott J, et al. (2025) Loss of PI5P4Kalpha Slows the Progression of a Pten Mutant Basal Cell Model of Prostate Cancer. Mol Cancer Res 23(1):33-45 |
| abstractText | Although early prostate cancer depends on the androgen receptor signaling pathway, which is predominant in luminal cells, there is much to be understood about the contribution of epithelial basal cells in cancer progression. Herein, we observe cell type-specific differences in the importance of the metabolic enzyme phosphatidylinositol 5-phosphate 4-kinase alpha (PI5P4Kalpha; gene name PIP4K2A) in the prostate epithelium. We report the development of a basal cell-specific genetically engineered mouse model targeting Pip4k2a alone or in combination with the tumor suppressor phosphatase and tensin homolog (Pten). PI5P4Kalpha is enriched in basal cells, and no major histopathologic changes were detectable following gene deletion. Notably, the combined loss of Pip4k2a slowed the development of Pten mutant mouse prostatic intraepithelial neoplasia. Through the inclusion of a lineage tracing reporter, we utilize single-cell RNA sequencing to evaluate changes resulting from in vivo downregulation of Pip4k2a and characterize cell populations influenced in the established Probasin-Cre- and cytokeratin 5-Cre-driven genetically engineered mouse model. Transcriptomic pathway analysis points toward the disruption of lipid metabolism as a mechanism for reduced tumor progression. This was functionally supported by shifts of carnitine lipids in LNCaP prostate cancer cells treated with siPIP4K2A. Overall, these data nominate PI5P4Kalpha as a target for PTEN mutant prostate cancer. Implications: PI5P4Kalpha is enriched in prostate basal cells, and its targeted loss slows the progression of a model of advanced prostate cancer. |
